Probiotic pretreatment improves survival and prevents gut mucosal barrier dysfunction in sepsis
© Calisto et al.; licensee BioMed Central Ltd. 2014
Published: 3 December 2014
The gut is the largest immune organ and plays a central role in the promotion of systemic inflammatory responses . Perturbations of intestinal epithelial homeostasis during sepsis include increased proinflammatory cytokine production, increased intestinal permeability and apoptosis [2–6]. Healthy gut is essential to promote host health and prevent organ dysfunction in sepsis. Probiotics seem to keep gut homeostasis through different pathways, such as the modulation of microbial activity, energy regulation, anti-inflammatory cytokine production, gene expression and cell differentiation . Probiotics have been shown an effective treatment in various clinical conditions, although the potential benefits of probiotic treatment in sepsis remain largely undefined. The aim of the present study was to investigate the effect of probiotic treatment on gut dysfunction and inflammatory signaling in septic rats.
Sepsis was induced by cecal ligation and puncture (CLP) in Wistar male rats (8 weeks old). They were pretreated with probiotics or vehicle once a day during 7 days before CLP. The chosen probiotic mixture contained 10 × 107 CFU Bifidobacterium longum, 10 × 106 CFU Lactobacillus bulgaricus, 10 × 106 CFU Lactobacillus acidophilus. Colonic tissue and serum samples were collected 24 hours after CLP for ELISA and protein expression analysis by western blotting.
Our results show that probiotics pretreatment fulfills a dual function at the intestinal mucosa: in addition to preventing intestinal permeability disruption, it also attenuates proinflammatory cytokine release, diminishing the exacerbate host's reaction to infection and offering a novel prophylactic strategy to sepsis.
- Clark JA, Coopersmith CM: Intestinal crosstalk: a new paradigm for understanding the gut as the 'motor' of critical illness. Shock 2007, 28: 384-393. 10.1097/shk.0b013e31805569dfView ArticlePubMedPubMed CentralGoogle Scholar
- Dominguez JA, Coopersmith CM: Can we protect the gut in critical illness? The role of growth factors and other novel approaches. Crit Care Clin 2010, 26: 549-565. 10.1016/j.ccc.2010.04.005View ArticlePubMedPubMed CentralGoogle Scholar
- Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA: Post-injury multiple organ failure: the role of the gut. Shock 2001, 15: 1-10.View ArticlePubMedGoogle Scholar
- Yu P, Martin CM: Increased gut permeability and bacterial translocation in Pseudomonas pneumonia-induced sepsis. Crit Care Med 2000, 28: 2573-2577.View ArticlePubMedGoogle Scholar
- Neal MD, Leaphart C, Levy R, Prince J, Billiar TR, Watkins S, Li J, Cetin S, Ford H, Schreiber A, et al.: Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006, 176: 3070-3079. 10.4049/jimmunol.176.5.3070View ArticlePubMedGoogle Scholar
- Clark JA, Gan H, Samocha AJ, Fox AC, Buchman TG, Coopersmith CM: Enterocyte-specific epidermal growth factor prevents barrier dysfunction and improves mortality in murine peritonitis. Am J Physiol Gastrointest Liver Physiol 2009, 297: G471-G479. 10.1152/ajpgi.00012.2009View ArticlePubMedPubMed CentralGoogle Scholar
- Sartor RB: Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 2005, 21: 44-50.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.